Thrombotic MPN patients carried almost exclusively JAK2 V617F mutation (90.6% of cases), this finding being consistent with the previously established etiological role of this mutation in MPN‐associated thrombosis.17 Here, JAK2 is linked to myeloproliferative neoplasm.